木瓜直播

While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group

"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy

Another vaccine option, updated ACIP recommendations, and data on a new monoclonal antibody

Decision was based on need for RSV protection in younger people with chronic conditions

However, questions remain about durability of vaccine protection, expert says

Clesrovimab reduced severe disease, hospitalizations in preterm and term healthy infants

But will benefits seen in Chinese trial translate to clinical improvement?

Paul Offit, MD, talks about the flu, RSV, and COVID vaccines for the 2024-2025 season

Initial trials were not powered to assess efficacy against RSV-associated hospitalization

Co-administration generally safe, could reduce vaccine burden, researchers say

Monoclonal antibody also reduced PICU admissions, need for ventilatory support

However, vaccine was associated with modest risk of maternal hypertensive disorders

Committee ditches shared decision-making, moves to risk-based approach

Arexvy now approved for people 50 years and older at increased risk of serious outcomes